RxDoctor Payments Data

Mrinali Gupta, MD

Ophthalmology · New York, NYNPI 1902037047

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $165,625 of the $181,523 with a category attached, or 91.2%. Alcon accounts for 70.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $49,746 and has fallen 71.9% since, to $14,002 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$181,523in general payments, 2019–2025

Across 145 payments — averaging $1251.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$128K
  • Alcon Research LLC$33K
  • AbbVie$9K
  • Carl Zeiss Meditec, Inc.$7K
  • Alimera Sciences, Inc.$2K
  • Ocular Therapeutix, Inc.$2K
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$165,62591%
  • Speaking & faculty fees$4,9403%
  • Travel & lodging$5,5423%
  • Food & beverage$5,3473%
  • Education$690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$181,523 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$1,405,003
Medicare patients
578
Services billed
17,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate212$6,395
MoxifloxacinMoxifloxacin Hcl99$2,393
Atropine Sulfate51$1,891
Brimonidine Tartrate16$1,771
Ketorolac Tromethamine84$1,290
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$600
Dorzolamide Hcl11$250
Latanoprost21$159
Timolol Maleate18$137

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →